Successful quality improvement project to increase hydroxyurea prescriptions for children with sickle cell anaemia.

Hydroxyurea (HU) is an effective but underused disease-modifying therapy for patients with sickle cell anaemia (SCA). EMBRACE SCD, a sickle cell disease treatment demonstration project, aimed to improve access to HU by increasing prescription (Rx) rates by at least 10% from baseline in children with SCA.The Model for Improvement was used as the quality improvement framework. HU Rx was assessed from clinical databases in three paediatric haematology centres. Children aged 9 months-18 years with SCA not on chronic transfusions were eligible for HU treatment. The health belief model was the conceptual framework to discuss with patients and promote HU acceptance. A visual aid showing erythrocytes under the effect of HU and the American Society of Hematology HU brochure were used as educational tools. At least 6 months after offering HU, a Barrier Assessment Questionnaire was given to assess reasons for HU acceptance and refusals. If HU was declined, the providers discussed with family again. We conducted chart audits to find missed opportunities to prescribe HU as one plan-do-study-act cycle.At initial measurement, 50.2% of 524 eligible patients had HU prescribed. During the testing and initial implementation phase, the mean performance after 10 data points was 53%. After 2 years, the mean performance was 59%, achieving an 11% increase in mean performance and a 29% increase from initial to the last measurement (64.8% HU Rx). During a 15-month period, 32.1% (N=168) of the eligible patients who were offered HU completed the barrier questionnaire with 19% (N=32) refusing HU, mostly based on not perceiving enough severity of their children's SCA or fearing side effects.Reviewing patient charts for missed opportunity of offering HU with feedback and evaluating the reasons of declining HU via a questionnaire were key components in increasing HU Rx in our population.

A Quality Improvement Approach to Ensuring Access to Specialty Care for Pediatric Patients.

Introduction: With pediatric rheumatologists in short supply, maximizing appointment availability and streamlining primary/specialty collaboration are essential. Lack of an efficient referral process impacts outcomes, quality of life, satisfaction, affordability, and resource allocation. Before this quality improvement project, our clinic had a 3- to 5-month backlog for new referrals. Methods: Using the model for improvement with numerous rapid-cycle plan-do-study-act cycles, this team restructured processes, developed a triage tool for communication across the care continuum, maximized staff roles in multiple areas, and instituted cross-disciplinary communication strategies to reduce appointment delays while significantly increasing efficiency. Results: The team succeeded in decreasing time from referral to specialty consult by 60%, decreasing no-show rates from 15% to 6%, and increasing throughput by an average of 45 more patients per month. Most new patients can now see our specialists within 23 days, meaning the children in our community have 65% shorter wait times for rheumatology services. Conclusion: The use of a triage algorithm with structured communication allows multidisciplinary care teams at both the referring and receiving providers to efficiently and accurately place patients into specialty care. This highly scalable and transferable project was accomplished with no direct financial outlay yet yielded significant returns by standardizing processes, empowering the entire care team to build skills, and improving communication.

Successful Implementation of the Eat Sleep Console Model of Care for Infants With NAS in a Community Hospital.

BACKGROUND: Opioid use across the United States is increasing. The concomitant rise in the incidence of neonatal abstinence syndrome (NAS) has made care of infants with this disease process a top priority for pediatric centers across the country. There is growing evidence that the Eat Sleep Console (ESC) model of care is superior to the established Finnegan Neonatal Abstinence Scoring System model. OBJECTIVES: We aimed to improve the care of infants with NAS by transitioning from the Finnegan Neonatal Abstinence Scoring System model to the ESC model of care. Our goal was to decrease the average length of stay from 11.77 to 5.94 days without having an increase in readmissions. METHODS: A multidisciplinary team was created. Education about NAS and ESC was created and distributed. Patients were admitted to the inpatient unit, and outcomes were observed. Standard quality improvement methodology was used for this intervention. RESULTS: After implementation of the ESC care model, average length of stay decreased to 5.94 days, with 0 patients readmitted or transferred for NAS-related complications. We saw a 48% reduction in average variable cost per patient. In addition to these reductions and savings, total per patient morphine exposure was reduced from 2.25 to 0.45 mg/kg, a 79% reduction in use. CONCLUSIONS: The ESC model of care was successfully implemented at our institution with resultant cost savings, decreased length of stay, and decreased medication use. Our work further supports the adoption of this new model of care for infants with NAS.